MAFD9
MCID: MJR024
MIFTS: 41

Major Affective Disorder 9 (MAFD9)

Categories: Genetic diseases, Mental diseases

Aliases & Classifications for Major Affective Disorder 9

MalaCards integrated aliases for Major Affective Disorder 9:

Name: Major Affective Disorder 9 57 13 71
Major Affective Disorder-9, Susceptibility to 57
Bipolar Affective Disorder 57
Major Affective Disorder-9 57
Bipolar Disorder 71
Mafd9 57

Classifications:



External Ids:

OMIM® 57 612372
MedGen 41 C2700440
UMLS 71 C0005586 C2700440

Summaries for Major Affective Disorder 9

MalaCards based summary : Major Affective Disorder 9, also known as major affective disorder-9, susceptibility to, is related to major affective disorder 1 and bipolar disorder. An important gene associated with Major Affective Disorder 9 is MAFD9 (Major Affective Disorder-9, Susceptibility To). The drugs Eleuthero and Coal tar have been mentioned in the context of this disorder. Affiliated tissues include brain, cortex and prefrontal cortex.

More information from OMIM: 612372

Related Diseases for Major Affective Disorder 9

Diseases in the Major Affective Disorder 1 family:

Major Affective Disorder 2 Major Affective Disorder 3
Major Affective Disorder 4 Major Affective Disorder 5
Major Affective Disorder 6 Major Affective Disorder 8
Major Affective Disorder 7 Major Affective Disorder 9

Diseases related to Major Affective Disorder 9 via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 179)
# Related Disease Score Top Affiliating Genes
1 major affective disorder 1 11.9
2 bipolar disorder 11.7
3 major affective disorder 5 11.6
4 major affective disorder 6 11.6
5 major affective disorder 8 11.5
6 major affective disorder 2 11.4
7 major affective disorder 3 11.4
8 major affective disorder 4 11.4
9 major affective disorder 7 11.4
10 mood disorder 10.8
11 schizophrenia 10.8
12 depression 10.7
13 endogenous depression 10.7
14 mental depression 10.7
15 bipolar i disorder 10.6
16 major depressive disorder 10.6
17 psychotic disorder 10.5
18 personality disorder 10.5
19 obsessive-compulsive disorder 10.5
20 schizoaffective disorder 10.5
21 alcohol dependence 10.4
22 tardive dyskinesia 10.4
23 hypothyroidism 10.4
24 substance abuse 10.4
25 borderline personality disorder 10.4
26 huntington disease 10.3
27 attention deficit-hyperactivity disorder 10.3
28 parkinsonism 10.3
29 cyclothymic disorder 10.3
30 anxiety 10.3
31 hydrocephalus 10.3
32 dementia 10.3
33 thalassemia 10.3
34 head injury 10.3
35 schizophrenia 1 10.2
36 frontotemporal dementia 10.2
37 mental health wellness 1 10.2
38 mental health wellness 2 10.2
39 alacrima, achalasia, and mental retardation syndrome 10.2
40 exanthem 10.2
41 physical disorder 10.2
42 thalassemia minor 10.2
43 movement disease 10.2
44 panic disorder 10.2
45 severe combined immunodeficiency 10.2
46 adenoma 10.2
47 hyperthyroidism 10.2
48 learning disability 10.2
49 substance dependence 10.2
50 darier-white disease 10.1

Comorbidity relations with Major Affective Disorder 9 via Phenotypic Disease Network (PDN):


Acute Cystitis Bipolar Disorder
Deficiency Anemia Heart Disease
Hypertension, Essential Hypothyroidism
Major Depressive Disorder Parkinson Disease, Late-Onset
Schizophreniform Disorder

Graphical network of the top 20 diseases related to Major Affective Disorder 9:



Diseases related to Major Affective Disorder 9

Symptoms & Phenotypes for Major Affective Disorder 9

Clinical features from OMIM®:

612372 (Updated 05-Mar-2021)

Drugs & Therapeutics for Major Affective Disorder 9

Drugs for Major Affective Disorder 9 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 411)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Eleuthero Approved, Experimental Phase 4
2
Coal tar Approved Phase 4 8007-45-2
3
Clozapine Approved Phase 4 5786-21-0 2818
4
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
5
Cocaine Approved, Illicit Phase 4 50-36-2 5760 446220
6
Sertraline Approved Phase 4 79617-96-2 68617
7
Loxapine Approved Phase 4 1977-10-2 3964
8
Paroxetine Approved, Investigational Phase 4 61869-08-7 43815
9
Donepezil Approved Phase 4 120014-06-4 3152
10
Methylphenidate Approved, Investigational Phase 4 113-45-1 4158
11
Norepinephrine Approved Phase 4 51-41-2 439260
12
Acetylcholine Approved, Investigational Phase 4 51-84-3 187
13
Histamine Approved, Investigational Phase 4 51-45-6, 75614-87-8 774
14
Ondansetron Approved Phase 4 99614-02-5 4595
15
Memantine Approved, Investigational Phase 4 19982-08-2 4054
16
Modafinil Approved, Investigational Phase 4 68693-11-8 4236
17
Acamprosate Approved, Investigational Phase 4 77337-76-9 71158
18
Naltrexone Approved, Investigational, Vet_approved Phase 4 16590-41-3 5360515
19
Galantamine Approved Phase 4 357-70-0 9651
20
Topiramate Approved Phase 4 97240-79-4 5284627
21
Ropinirole Approved, Investigational Phase 4 91374-20-8, 91374-21-9 5095 497540
22
Oxcarbazepine Approved Phase 4 28721-07-5 34312
23
Tranylcypromine Approved, Investigational Phase 4 155-09-9 441233
24
Iloperidone Approved Phase 4 133454-47-4 71360
25
Nortriptyline Approved Phase 4 72-69-5 4543
26
Mirtazapine Approved Phase 4 85650-52-8, 61337-67-5 4205
27
Exenatide Approved, Investigational Phase 4 141758-74-9 15991534
28
Levetiracetam Approved Phase 4 102767-28-2 441341
29
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
30
Chlorpromazine Approved, Investigational, Vet_approved Phase 4 50-53-3 2726
31
Methohexital Approved Phase 4 151-83-7 9034
32
Dipyridamole Approved Phase 4 58-32-2 3108
33
Brexpiprazole Approved, Investigational Phase 4 913611-97-9 11978813
34
Succinylcholine Approved Phase 4 306-40-1 5314
35
Metformin Approved Phase 4 657-24-9 14219 4091
36
Minocycline Approved, Investigational Phase 4 10118-90-8 5281021
37
Aspirin Approved, Vet_approved Phase 4 50-78-2 2244
38
Atorvastatin Approved Phase 4 134523-00-5 60823
39
Carbamazepine Approved, Investigational Phase 4 298-46-4 2554
40
Varenicline Approved, Investigational Phase 4 249296-44-4 5310966
41
Nicotine Approved Phase 4 54-11-5 942 89594
42
Racepinephrine Approved Phase 4 329-65-7 838
43
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
44
Methylcobalamin Approved, Investigational Phase 4 13422-55-4
45
Hydroxocobalamin Approved Phase 4 13422-51-0 11953898 15589840
46
Acetaminophen Approved Phase 4 103-90-2 1983
47
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
48
Simvastatin Approved Phase 4 79902-63-9 54454
49
Angiotensin II Approved, Investigational Phase 4 68521-88-0, 4474-91-3, 11128-99-7 172198
50
Losartan Approved Phase 4 114798-26-4 3961

Interventional clinical trials:

(show top 50) (show all 1265)
# Name Status NCT ID Phase Drugs
1 Algorithm Guided Treatment Strategies for Bipolar Depression Unknown status NCT01938859 Phase 4 Lithium;Quetiapine;Shuganjieyu capsule
2 Assessing the Efficacy of Left Repetitive Transcranial Magnetic Stimulation (rTMS) as an Adjunctive Treatment to Mood Stabilizers for the Treatment of Bipolar Depression Unknown status NCT01583023 Phase 4 Bupropion
3 Reversal of Antipsychotic-Induced Hyperprolactinemia, Weight Gain, Hyperglycemia and Dyslipidemia by Aripiprazole Add-on Therapy in the Treatment of Schizophrenia and Bipolar Disorder: An Open-Label Trial Unknown status NCT00541554 Phase 4 Abilify (aripiprazole)
4 A Randomized Controlled Trial to Evaluate the Effectiveness of Clozapine Versus Olanzapine, Quetiapine or Risperidone in Treatment Resistant Bipolar Disorder Unknown status NCT02562287 Phase 4 Clozapine;Risperidone;Olanzapine;Quetiapine
5 Neurofunctional and Neurochemical Markers of Treatment Response in Bipolar Disorder Unknown status NCT00608075 Phase 4 lithium;Lithium
6 Open Label Prophylaxis Study of Lithium Plus Extended- Release Carbamazepine (Equetro®) Combination for Rapid Cycling Bipolar Disorder Unknown status NCT00325286 Phase 4 Lithium Plus Extended- Release Carbamazepine
7 An Open Label, Multicenter, Single Arm, 4-Week Study to Evaluate the Efficacy and Safety of Flexible Dose of Quetiapine Fumarate (Seroquel) Switching From Other Drugs in the Treatment of Acute Manic Patients With Bipolar Disorder Unknown status NCT00837343 Phase 4 quetiapine fumarate tablet (Seroquel)
8 Assessment and Follow Up Study of Children and Adolescent With Bipolar Disorder Unknown status NCT01000402 Phase 4 Psychopharmacotherapy
9 Neuroimaging Study of Risk Factors for Adolescent Bipolar Disorder Unknown status NCT02478788 Phase 4 mixed amphetamine salts-extended release (MAS-XR);Placebo
10 A Placebo Controlled Trial of the Dopamine D-2 Receptor Agonist Ropinirole in Treatment of 60 Patients With Refractory Bipolar I and II Depression. Unknown status NCT00335205 Phase 4 ropinirole
11 Comparative Efficacy and Acceptability of Lithium, Valproate, Oxcarbazepine, Quetiapine, Olanzapine, and Ziprasidone in Bipolar I Disorder, Manic or Mixed Phase Unknown status NCT01893229 Phase 4 Lithium;Valproate;Oxcarbazepine;Quetiapine;Olanzapine;Ziprasidone
12 Effects of N-Acetyl-Cysteine on Oxidative Stress Biomarkers in Bipolar Patients With and Without Tobacco Use Disorder Unknown status NCT02252341 Phase 4
13 Exploring Alterations of Central Autonomic Modulation in Patients With Bipolar Depression Unknown status NCT01213121 Phase 4 Quetiapine
14 Reduction of Cardiovascular Risk in Severe Mental Illness Prescribing and Using Better and More Appropriated Drugs Unknown status NCT01182012 Phase 4
15 An Exploratory Randomized Open Comparison of Oxtellar XR® vs Oxcarbazepine IR (Trileptal®) for the Treatment of Bipolar Depression Unknown status NCT03567681 Phase 4 Extended release oxcarbazepine vs Immediate release oxcarbazepine
16 A Randomized Open-label Active-controlled Study to Evaluate the Efficacy and Safety of Utapine Versus Seroquel in Patients With Bipolar Mania Unknown status NCT01043679 Phase 4 Utapine;Seroquel
17 Clinical Psychopharmacology Division Institute of Mental Health, Peking University Unknown status NCT03148535 Phase 4 Lithium Carbonate;lithium carbonate combined with SSRI antidepressant treatment
18 Longitudinal Study on the Neuroprotective and Neurotrophic Effects of Lithium in Bipolar Disorder: Identification of Cellular and Molecular Targets Clinically Relevant Completed NCT01919892 Phase 4 Lithium
19 Open-Label Comparative Study of Risperidone Versus Olanzapine for Mania in Preschool Children 4 to 6 Years of Age With Bipolar Spectrum Disorder Completed NCT00181935 Phase 4 risperidone (Risperdal);olanzapine (Zyprexa)
20 Open-Label Study of Quetiapine for Mania In Preschool Children 4 to 6 Years of Age With Bipolar and Bipolar Spectrum Disorder Completed NCT00181883 Phase 4 quetiapine
21 A Pilot Open Study of the Safety and Effectiveness of Lamotrigine for the Treatment of Mania in Youth Ages 6-17 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorders Completed NCT00181844 Phase 4 lamotrigine
22 Open-Label Study of Divalproex Sodium Extended Release for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181727 Phase 4 divalproex sodium extended release
23 Metformin for Treatment Antipsychotic-induced Metabolic Syndrome in Bipolar Disorder Patients Completed NCT02644577 Phase 4 Metformin
24 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Cocaine Dependence Completed NCT00223210 Phase 4 Quetiapine;PLacebo
25 Quetiapine for Bipolar Disorder and Alcohol Dependence Completed NCT00457197 Phase 4 Placebo;Quetiapine
26 Open-Label Pilot Study of Aripiprazole for the Treatment of Mania in Children and Adolescents With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181779 Phase 4 aripiprazole (Abilify)
27 Lamictal for Use in Treatment of Bipolar Disorder In Adults. A Practical Clinical Assessment of Tolerability and Clinical Effectiveness. Completed NCT00067938 Phase 4 lamotrigine
28 Metabolic Effects of Melatonin in Patients Treated With Second Generation Antipsychotics Completed NCT01811160 Phase 4 Melatonin;Placebo
29 A Phase IV, Open-label, Non-randomized, Clinical Trial to Evaluate the Safety of Self-administered ADASUVE® (Staccato Loxapine for Inhalation) in Agitated Patients Outside the Hospital Setting Completed NCT02525991 Phase 4
30 A Randomized, Open-label, Trial of Lithium Versus Paroxetine in Subjects With Major Depression Who Have a Family History of Bipolar Disorder or Completed Suicide Completed NCT01416220 Phase 4 Lithium;Paroxetine
31 A Double-Blind, Placebo-Controlled Evaluation of The Efficacy and Safety of AChE Inhibitor Donepezil As Adjunctive Treatment to Mood Stabilizers in Acute Mania Completed NCT01191918 Phase 4 Donepezil and Lithium;Placebo plus Lithium
32 An Open-labeled, Parallel-group, Single-blinded (Rater) Pilot Study to Investigate the Neuroprotective Effects of of Low-dose Lithium in Young Subjects at Ultra High Risk (UHR) of Developing a First-episode Psychotic Disorder Completed NCT00202306 Phase 4 lithium carbonate
33 Open-Label Study of Concerta in the Treatment of ADHD in Youth and Adults With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181987 Phase 4 methylphenidate HCl (Concerta)
34 Open-Label Study of Ziprasidone for the Treatment of Mania in Children and Adolescents With Bipolar Spectrum Disorder Completed NCT00181922 Phase 4 ziprasidone (Geodon)
35 Open-Label Study of Equetro for the Treatment of Mania in Children Ages 6-12 With Bipolar I, Bipolar II, and Bipolar Spectrum Disorder Completed NCT00181870 Phase 4 carbamazepine ER (Equetro)
36 Acute Antidepressant Therapy in Bipolar II Major Depression Completed NCT00641927 Phase 4 Venlafaxine;Lithium Carbonate
37 Extended Duration Pharmacotherapy for Prevention of Relapse to Smoking Completed NCT00621777 Phase 4 Varenicline;Placebo
38 A Randomized, Sham Controlled, Crossover Trial of rTMS for Bipolar Depression Completed NCT00186758 Phase 4
39 Multi-center, Double-blind, Randomized, Comparative Phase 4 Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify and Depakote in 24-week Treatment of Mania in Patients With Bipolar Disorder Remitted After 6-week Treatment With Abilify and Depakote Completed NCT00545675 Phase 4 Abilify(aripiprazole);Depakote (divalproate)
40 Multi-center, Single Arm, Open Phase IV Clinical Trial to Evaluate the Efficacy and Safety of Co-administration of Abilify With Depakote in the 6-week Treatment of Acute Mania in Patients With Bipolar Disorder Completed NCT00545142 Phase 4 Abilify(Aripiprazole);Depakote(Divalproate)
41 Ondansetron for Bipolar Disorder and Alcohol Use Disorders Completed NCT02082678 Phase 4 Ondansetron;Placebo
42 Memantine and Cognitive Dysfunction in Bipolar Disorder Completed NCT00586066 Phase 4 Memantine;Placebo
43 A Randomized, Double-Blind, Placebo-Controlled Study of Ziprasidone in Bipolar Disorder With Comorbid Lifetime Panic or Generalized Anxiety Disorder Completed NCT01172652 Phase 4 Ziprasidone;Placebo
44 Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder With Modafinil Completed NCT01965925 Phase 4 Modafinil;Placebo
45 Naltrexone for Bipolar Disorder and Alcohol Dependence Completed NCT00223275 Phase 4 Naltrexone
46 A Randomized, Double-Blind, Placebo-Controlled Add-On Trial of Quetiapine in Patients With Bipolar Disorder and Alcohol Abuse/ Dependence. Completed NCT00223249 Phase 4 Quetiapine
47 Divalproex ER vs. Risperidone for Bipolar Disorder With Comorbid Substance Use Disorder Completed NCT00203528 Phase 4 divalproex sodium ER;risperidone
48 A Phase 4 Double-Blind, Placebo-Controlled Study of Galantamine to Improve Cognitive Dysfunction in Bipolar Disorder Completed NCT00195845 Phase 4 Galantamine;Placebos
49 Varenicline Treatment for Smoking Cessation in Patients With Bipolar Disorder Completed NCT01010204 Phase 4 Varenicline;Placebo
50 Ziprasidone Switching in Response to Adherence and Psychotropic-Related Weight Gain Concerns Among Patients With Bipolar Disorder Completed NCT01293825 Phase 4 ziprasidone

Search NIH Clinical Center for Major Affective Disorder 9

Inferred drug relations via UMLS 71 / NDF-RT 51 :


Carbamazepine
Clonazepam
Clozapine
CLOZAPINE (CARACO)
CLOZAPINE (CLOZARIL)
CLOZAPINE (IVAX)
CLOZAPINE (TEVA)
CLOZAPINE (VERSACLOZ)
Divalproex Sodium
Fazaclo
gabapentin
gabapentin enacarbil
lamotrigine
Lithium
Lithium Aspartate
Lithium Carbonate
lithium citrate
Mylan brand of clozapine
olanzapine
quetiapine
Quetiapine fumarate
Risperidone
Sodium Valproate
tiagabine
Tiagabine hydrochloride
topiramate
UDL brand of clozapine
Valproic Acid

Genetic Tests for Major Affective Disorder 9

Anatomical Context for Major Affective Disorder 9

MalaCards organs/tissues related to Major Affective Disorder 9:

40
Brain, Cortex, Prefrontal Cortex, Amygdala, Thyroid, Cingulate Cortex, Eye

Publications for Major Affective Disorder 9

Articles related to Major Affective Disorder 9:

(show top 50) (show all 27021)
# Title Authors PMID Year
1
Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. 61 57
18711365 2008
2
Clinical characteristics of bipolar disorders with postpartum depressive onset. 61
33347983 2021
3
Gut microbiota-derived vitamins - underrated powers of a multipotent ally in psychiatric health and disease. 61
33428888 2021
4
Body mass index and blood pressure in bipolar patients: Target cardiometabolic markers for clinical practice. 61
33445086 2021
5
The risk of anxiety disorders in children of parents with severe psychiatric disorders: a systematic review and meta-analysis. 61
33422825 2021
6
Role of interleukin 8 in depression and other psychiatric disorders. 61
33186640 2021
7
Chronic lithium exposure attenuates ketamine-induced mania-like behavior and c-Fos expression in the forebrain of mice. 61
33450292 2021
8
Endocannabinoid system in psychotic and mood disorders, a review of human studies. 61
32898588 2021
9
Positional cloning and comprehensive mutation analysis of a Japanese family with lithium-responsive bipolar disorder identifies a novel DOCK5 mutation. 61
32920599 2021
10
A peripheral inflammatory signature discriminates bipolar from unipolar depression: A machine learning approach. 61
33045321 2021
11
Characterizing the gut microbiota in adults with bipolar disorder: a pilot study. 61
31132957 2021
12
The mental health and lifestyle impacts of COVID-19 on bipolar disorder. 61
33422820 2021
13
Manic and euthymic states in pediatric bipolar disorder patients during an emotional Go/Nogo task: A functional magnetic resonance imaging study. 61
33401127 2021
14
Individualized identification of first-episode bipolar disorder using machine learning and cognitive tests. 61
33445089 2021
15
Ouabain induces memory impairment and alter the BDNF signaling pathway in an animal model of bipolar disorder: Cognitive and neurochemical alterations in BD model. 61
33601696 2021
16
Clinical and neurostructural characteristics among youth with familial and non-familial bipolar disorder: Family history and youth bipolar disorder. 61
33601710 2021
17
Does cognitive impairment in bipolar disorder impact on a SIMPLe app use? 61
33422826 2021
18
Children with euthymic bipolar disorder during an emotional go/nogo task: Insights into the neural circuits of cognitive-emotional regulation. 61
33445090 2021
19
Trajectories of medication adherence in patients with Bipolar Disorder along 2 years-follow-up. 61
33601722 2021
20
Interpretation bias training for bipolar disorder: A randomized controlled trial. 61
33601731 2021
21
Inferior frontal gyrus seed-based resting-state functional connectivity and sustained attention across manic/hypomanic, euthymic and depressive phases of bipolar disorder. 61
33601737 2021
22
Bipolar disorder: An evolutionary psychoneuroimmunological approach. 61
33421542 2021
23
Covid-19 pandemic and lockdown impacts: A description in a longitudinal study of bipolar disorder. 61
33601700 2021
24
Bipolar Disorder and Psychosis in Autism. 61
33526231 2021
25
Bedroom light exposure at night and obesity in individuals with bipolar disorder: A cross-sectional analysis of the APPLE cohort. 61
33306979 2021
26
Recent developments in Phelan-McDermid syndrome research: an update on cognitive development, communication and psychiatric disorders. 61
33278153 2021
27
Resurrecting the discussion on neurotoxicity of lithium at therapeutic levels. 61
33136660 2021
28
Effectiveness of risk minimisation measures for valproate: A cross-sectional survey among physicians in Europe. 61
33216434 2021
29
A nation-wide population-based longitudinal study mapping physical diseases in patients with bipolar disorder and their siblings. 61
33387742 2021
30
Cortical activity measured by functional near infrared spectroscopy during a theory of mind task in subjects with schizophrenia, bipolar disorder and healthy controls. 61
33421860 2021
31
Cognitive heterogeneity in the offspring of patients with schizophrenia or bipolar disorder: a cluster analysis across family risk. 61
33601716 2021
32
The shared genetic architecture of schizophrenia, bipolar disorder and lifespan. 61
32772156 2021
33
Systemic inflammation and grey matter volume in schizophrenia and bipolar disorder: Moderation by childhood trauma severity. 61
32540496 2021
34
A genome-wide association study identifies a gene network associated with paranoid schizophrenia and antipsychotics-induced tardive dyskinesia. 61
33065217 2021
35
Targeting the microbiome-gut-brain axis for improving cognition in schizophrenia and major mood disorders: A narrative review. 61
33045322 2021
36
Gut microbiota, kynurenine pathway and mental disorders - Review. 61
33203568 2021
37
fNIRS study of prefrontal activation during emotion recognition-A Potential endophenotype for bipolar I disorder? 61
33601730 2021
38
Deciphering the multi-scale mechanisms of Tephrosia purpurea against polycystic ovarian syndrome (PCOS) and its major psychiatric comorbidities: Studies from network pharmacological perspective. 61
33383117 2021
39
Reverse translational analysis of clinically reported, lamotrigine-induced cardiovascular adverse events using the halothane-anesthetized dogs. 61
33136260 2021
40
Psychotic symptoms during bipolar depressive episodes and suicidal ideation. 61
33601702 2021
41
A Survey of Electroconvulsive Therapy in Finland. 61
32658056 2021
42
Cognitive remediation to improve the vocational outcomes of people with severe mental illness. 61
31752647 2021
43
Efficacy of cariprazine in bipolar I depression across patient characteristics: a post hoc analysis of pooled randomized, placebo-controlled studies. 61
33230026 2021
44
Distribution and overlap of entorhinal, premotor, and amygdalar connections in the monkey anterior cingulate cortex. 61
32677044 2021
45
Black cohosh associated mania in a patient with unipolar depression. 61
32955954 2021
46
Effects of tDCS on neuroplasticity and inflammatory biomarkers in bipolar depression: Results from a sham-controlled study. 61
33022345 2021
47
Identifying Anticipated Events of Future Clinical Trials by Leveraging Data from the Placebo Arms of Completed Trials. 61
33165761 2021
48
Bipolar disorder: Prevalence, help-seeking and use of mental health care in England. Findings from the 2014 Adult Psychiatric Morbidity Survey. 61
33422818 2021
49
How to project oneself without positive and integrated memories? Exploration of self-defining memories and future projections in bipolar disorder. 61
33524807 2021
50
Correction to: Positional cloning and comprehensive mutation analysis of a Japanese family with lithium-responsive bipolar disorder identifies a novel DOCK5 mutation. 61
33077897 2021

Variations for Major Affective Disorder 9

Expression for Major Affective Disorder 9

Search GEO for disease gene expression data for Major Affective Disorder 9.

Pathways for Major Affective Disorder 9

GO Terms for Major Affective Disorder 9

Sources for Major Affective Disorder 9

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Mar-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....